UPDATE 1-Samsung Bioepis seeks Europe approval for its Humira copy

July 18, 2016 1:20 AM

29 0

* Unclear when Humira biosimilar would start sales (Adds background on Samsung Bioepis)

SEOUL, July 18 Biosimilars maker Samsung Bioepis, part of South Korea's top family-run conglomerate Samsung Group, said on Monday it is seeking regulatory approval in Europe to sell its copy of AbbVie Inc's rheumatoid arthritis drug Humira.

Also read: Kroger’s New Approach to Stocking Shelves Is Boosting Earnings

Read more

To category page